{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:46:15Z","timestamp":1767980775058,"version":"3.49.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>Indoleamine 2-3 dioxygenase 1 (IDO1) expression may contribute to immunologic escape by melanoma metastases. However, a recent clinical trial failed to identify any clinical benefits of IDO1 inhibition in patients with unresectable metastatic melanoma, and prior characterizations of IDO1 expression have predominately studied primary lesions and local metastases, generating uncertainty regarding IDO1 expression in distant metastases. We hypothesized that IDO1 expression in such lesions would be low and correlated with decreased overall survival (OS). Metastases from patients (n=96) with stage IIIb to IV melanoma underwent tissue microarray construction and immunohistochemical staining for IDO1. Th1-related gene expression was determined quantitatively. Associations between OS and IDO1 expression were assessed with multivariate models. Of 96 metastatic lesions, 28% were IDO<jats:sup>pos<\/jats:sup>, and 85% exhibited IDO1 expression in &lt;10% of tumor cells. IDO<jats:sup>pos<\/jats:sup> lesions were associated with improved OS (28.9 vs. 10.5\u2009mo, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.02) and expression of Th1-related genes. OS was not associated with IDO1 expression in a multivariate analysis of all patients; however, IDO1 expression (hazard ratio=0.25, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.01) and intratumoral CD8<jats:sup>+<\/jats:sup> T-cell density (hazard ratio=0.99, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.01) were correlated with OS in patients who underwent metastasectomy with curative-intent. IDO<jats:sup>pos<\/jats:sup> metastases were less likely to recur after metastasectomy (54% vs. 16%, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.01). IDO1 expression was low in melanoma metastases and correlated with OS after metastasectomy with curative-intent. Intratumoral CD8<jats:sup>+<\/jats:sup> T cells and Th1-related genes were correlated with IDO1 expression, as was tumor recurrence. These suggest that IDO1 expression may be a marker of immunologic tumor control, and may inform participant selection in future trials of IDO1 inhibitors.<\/jats:p>","DOI":"10.1097\/pas.0000000000001622","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T23:40:04Z","timestamp":1605915604000},"page":"787-795","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["IDO1 Expression in Melanoma Metastases Is Low and Associated With Improved Overall Survival"],"prefix":"10.1097","volume":"45","author":[{"given":"Kevin T.","family":"Lynch","sequence":"first","affiliation":[{"name":"Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Gradecki","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minyoung","family":"Kwak","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max O.","family":"Meneveau","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nolan A.","family":"Wages","sequence":"additional","affiliation":[{"name":"Public Health Sciences, University of Virginia, Charlottesville, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro A.","family":"Gru","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig L.","family":"Slingluff","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: a gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat Med"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1084\/jem.189.9.1363","article-title":"Inhibition of T cell proliferation by macrophage tryptophan catabolism","volume":"189","author":"Munn","year":"1999","journal-title":"J Exp Med"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2174\/1568009615666151030102250","article-title":"Indoleamine 2,3-dioxygenase (IDO): biology and target in cancer immunotherapies","volume":"16","author":"Selvan","year":"2016","journal-title":"Curr Cancer Drug Targets"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000096906","article-title":"Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients","volume":"214","author":"Weinlich","year":"2007","journal-title":"Dermatology"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/JCO.2018.36.15_suppl.3033","article-title":"Pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma","volume":"36","author":"Slingluff","year":"2018","journal-title":"J Clin Oncol"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J Clin Oncol"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00281-018-0702-0","article-title":"Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond","volume":"41","author":"Muller","year":"2019","journal-title":"Semin Immunopathol"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jid.2017.09.036","article-title":"Indoleamine 2,3-dioxygenase expression in primary cutaneous melanoma correlates with breslow thickness and is of significant prognostic value for progression-free survival","volume":"138","author":"Rubel","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/his.13814","article-title":"Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment","volume":"74","author":"Gide","year":"2019","journal-title":"Histopathology"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.13100","article-title":"Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?","volume":"171","author":"Chevolet","year":"2014","journal-title":"Br J Dermatol"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.4161\/cc.8.12.8745","article-title":"Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival","volume":"8","author":"Brody","year":"2009","journal-title":"Cell Cycle"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"e1235107","DOI":"10.1080\/2162402X.2016.1235107","article-title":"PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: correlation with tumor-infiltrating immune cells and clinical outcome","volume":"5","author":"Obeid","year":"2016","journal-title":"Oncoimmunology"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","article-title":"Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma","volume":"72","author":"Erdag","year":"2012","journal-title":"Cancer Res"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/PGP.0000000000000494","article-title":"Targetable immune regulatory molecule expression in high-grade serous ovarian carcinomas in African American women: a study of PD-L1 and IDO in 112 cases from the African American Cancer Epidemiology Study (AACES)","volume":"38","author":"Mills","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41379-018-0039-1","article-title":"Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas","volume":"31","author":"Mills","year":"2018","journal-title":"Mod Pathol"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/his.13723","article-title":"PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy","volume":"74","author":"Chinn","year":"2019","journal-title":"Histopathology"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/s41379-018-0061-3","article-title":"IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1","volume":"31","author":"Dill","year":"2018","journal-title":"Mod Pathol"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/PAS.0000000000001099","article-title":"Indoleamine-2,3-dioxygenase in non-small cell lung cancer: a targetable mechanism of immune resistance frequently coexpressed with PD-L1","volume":"42","author":"Volaric","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3390\/cancers11020169","article-title":"Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression predicts poor pathologic response and recurrence in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy","volume":"11","author":"Zhou","year":"2019","journal-title":"Cancers"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ebiom.2019.09.038","article-title":"DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients\u2019 survival, immune cell infiltrates, mutational load, and interferon \u03b3 signature","volume":"48","author":"Sailer","year":"2019","journal-title":"EBioMedicine"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"voom: precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fimmu.2014.00230","article-title":"The role of placental tryptophan catabolism","volume":"5","author":"Sedlmayr","year":"2014","journal-title":"Front Immunol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4137\/IJTR.S38355","article-title":"The kynurenine pathway is a double-edged sword in immune-privileged sites and in cancer: implications for immunotherapy","volume":"9","author":"Routy","year":"2016","journal-title":"Int J Tryptophan Res"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/0008-5472.CAN-13-1656","article-title":"Mesenchymal stem cells employ IDO to regulate immunity in tumor microenvironment","volume":"74","author":"Ling","year":"2014","journal-title":"Cancer Res"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"71249","DOI":"10.18632\/oncotarget.19531","article-title":"Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy","volume":"8","author":"Medrano","year":"2017","journal-title":"Oncotarget"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"127.e15","DOI":"10.1016\/j.cell.2017.06.016","article-title":"IFN\u03b3-dependent tissue-immune homeostasis is co-opted in the tumor microenvironment","volume":"170","author":"Nirschl","year":"2017","journal-title":"Cell"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and tregs in the melanoma tumor microenvironment is driven by CD8+ T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-67577-0_2","article-title":"Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment","volume":"1036","author":"Gajewski","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1038\/s41467-019-12361-9","article-title":"Metabolomic adaptations and correlates of survival to immune checkpoint blockade","volume":"10","author":"Li","year":"2019","journal-title":"Nat Commun"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejca.2017.01.011","article-title":"The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy","volume":"76","author":"Brochez","year":"2017","journal-title":"Eur J Cancer"},{"key":"R34-20250608","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrc2639","article-title":"Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?","volume":"9","author":"L\u00f6b","year":"2009","journal-title":"Nat Rev Cancer"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T22:04:40Z","timestamp":1749420280000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001622","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,17]]}}}